Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Plus Docetaxel in Advanced Gastric Cancer
NCT02596256Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2016
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in gastric cancer (GC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02596256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596256.